arrow
L

Louis Fries

University of Witwatersrand
H指数:47
被引数:8,348

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Anti-spike IgG4 and Fc effector responses: The impact of SARS-CoV-2 vaccine platform–specific priming and immune imprinting

抗刺突蛋白IgG4和Fc效应反应:SARS-CoV-2疫苗平台特异性初始免疫和免疫印记的影响

2025-06-260
OA
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M™ adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial
2024-12-120
OAAI
A Modified Novel Validated High-Throughput Hemagglutinin Inhibition Assay Using Recombinant Virus-like Particles and Human Red Blood Cells for the Objective Evaluation of Recombinant Hemagglutinin Nanoparticle Seasonal Influenza Vaccine
2024-11-190
OAAI
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine

NVX-CoV2373疫苗的安全性、有效性和免疫原性

2023-06-0512
OA
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial

布基纳法索儿童R21/Matrix-M疫苗对临床疟疾的疗效和免疫原性: 1/2b期随机对照试验

2022-12-01142
OAAI
Influenza A(H7N9) Pandemic Preparedness: Assessment of the Breadth of Heterologous Antibody Responses to Emerging Viruses from Multiple Pre-Pandemic Vaccines and Population Immunity

甲型流感 (H7N9) 大流行的防备: 评估对来自多种大流行前疫苗和人群免疫的新兴病毒的异源抗体反应的广度

2022-11-015
OAAI
Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial
2022-10-1036
OAAI
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

布基纳法索儿童季节性接种低剂量候选疟疾疫苗R21和佐剂matrix-m的疗效: 一项随机对照试验

LANCET
IF88.5
2021-05-01270
OAAI
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

SARS-CoV-2刺突糖蛋白候选疫苗在狒狒中的NVX-CoV2373免疫原性及对小鼠的保护作用

2021-01-14338
OAAI
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
2020-12-10870
OAAI